Figure 1From: Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-lifeRelationship between RG-2 glioma tumor location and volume and modeled baseline pharmacokinetic parameters. (A) Ktrans (transvascular flow rate, 1/min), (B) ve (extravascular extracellular space, fraction), (C) vp (vascular plasma volume, fraction). Anterior brain gliomas, N = 42; Posterior brain gliomas, N = 41.Back to article page